Case Report: Two cases of immune-associated myocarditis caused by tislelizumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41256312/
The current phase of immune checkpoint inhibitors has improved the clinical outcomes of many cancer therapies; however, these agents may also lead to some high-consequence immune-related adverse events. We report...
Two patients developed tislelizumab-associated myocarditis—one fatal, one responsive to high-dose steroids. Despite rarity, mortality is high, underscoring need for vigilance, early recognition, and prompt treatment of this immune-related toxicity.
APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37461590/
APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are...
EGFR inhibition induces APOBEC3 activity, enabling drug-tolerant persister survival and promoting T790M mutations and squamous transdifferentiation. Targeting ΔNp63 may help overcome APOBEC-driven resistance in EGFR-mutant lung cancer.
Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38226837/
Hypoxia induced the lactylation of SOX9 to promote stemness, migration, and invasion via promoting glycolysis. The findings suggested that targeting hypoxia may be an effective way for NSCLC treatment and...
Hypoxia promotes NSCLC stemness, migration, and invasion by inducing glycolysis-driven lactylation of SOX9; inhibiting glycolysis or SOX9 reduces tumor growth, highlighting a therapeutic target.
Comparative Safety Assessment of High and Low Doses of Anlotinib in Combination with PD-1 Monoclonal Antibody for Advanced Non-small Cell Lung Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38430167/
Findings suggest that combining low-dose AN with PD-1 monoclonal antibody therapy is a safer approach in the treatment of advanced NSCLC. These findings advocate for the adoption of a tailored,...
In advanced NSCLC, low-dose anlotinib (8–10 mg) combined with PD-1 inhibitors showed similar efficacy but fewer adverse effects and better immune function than high-dose (12 mg), supporting a safer, patient-tailored regimen.
Comparative Safety Assessment of High and Low Doses of Anlotinib in Combination with PD-1 Monoclonal Antibody for Advanced Non-small Cell Lung Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38430167/
Findings suggest that combining low-dose AN with PD-1 monoclonal antibody therapy is a safer approach in the treatment of advanced NSCLC. These findings advocate for the adoption of a tailored,...
In advanced NSCLC, combining low-dose anlotinib with PD-1 antibody provided similar efficacy but fewer adverse effects and inflammatory responses than high-dose therapy, supporting a safer, patient-centered dosing approach for improved tolerance.